pone.0275794.s001.doc (218.5 kB)
CONSORT 2010 checklist of information to include when reporting a randomised trial*.
journal contribution
posted on 2022-10-10, 17:38 authored by Andrea R. Thurman, Vivian Brache, Leila Cochon, Louise A. Ouattara, Neelima Chandra, Terry Jacot, Nazita Yousefieh, Meredith R. Clark, Melissa Peet, Homaira Hanif, Jill L. Schwartz, Susan Ju, Mark A. Marzinke, David W. Erikson, Urvi Parikh, Betsy C. Herold, Raina N. Fichorova, Elizabeth Tolley, Gustavo F. Doncel(DOC)
History
Usage metrics
Categories
Keywords
significantly higher ratesshow /# nct03279120secreted soluble proteinsmultipurpose prevention technologiesml within 2hmg within 72hrsmg throughout 90dlower insler scores87 – 98immune cell densitygenital tract histologyex vivo 3 day interruptionserious adverse eventsdiv >< pcervical mucus qualitylng ivr userslng caused changeswomen using tfvplacebo controlled phasecervical mucusadverse eventsvitro mucosal histologyimmune mediatorsday cyclesivr removalivr insertionlng uselng exposurelng concentrationwomen usedunintended pregnancytfv concentrationssperm penetrationsignificant changesrectal fluidsovulation compatiblemultiple compartmentsmpts ),menstrual cycleslighter bleedingintravaginal ringhiv replicationhighly desirablefold reductionfewer dayseight womenectocervical tissuesdecreasing quicklycycle ),cervicovaginal tissue90 days500 ng000 fmol